FlashFeed
๐Ÿ“ˆ
๐Ÿ“ˆ Business

Novo Nordisk shares drop 9% after heart drug ziltivekimab fails clinical trial

Novo Nordisk shares fell 9% after its experimental drug ziltivekimab failed to produce a statistically meaningful reduction in major cardiovascular adverse events in a clinical trial. The company announced the results on Friday.

Similar stories

๐Ÿฅ Health Novo Nordisk's anti-inflammation drug fails heart disease trial โ€” shares drop 7% STAT News ยท 18h ago ๐Ÿ“ˆ Business Shareholders Sue Novo Nordisk Over Misleading Claims on Weight-Loss Drug CagriSema CNBC ยท 2d ago ๐Ÿ“ˆ Business AstraZeneca shares drop over 10% after rare heart drug trial fails Bloomberg ยท 22d ago

Should a single drug trial failure have such a large impact on a major pharma company's valuation?

CNBC ยท 19h ago ยท Source โ†—

Comments

No comments yet